Aclaris Therapeutics Inc. Common Stock (ACRS)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor first, and Aclaris does not fit the kind of business I normally seek. It is a clinical-stage biopharmaceutical company with 69 employees, developing immuno-inflammatory candidates, including Bosakitug. The financial record shows why the Lynch category is none: losses in each of the last four years. Revenue fell from $31.2M in FY2023 to $18.7M in FY2024 and $7.8M in FY2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.6M and net income was -$21.5M; in fiscal Q1 2026, revenue was $2.0M and net income was -$19.8M. Trailing free cash flow is -$62.2M, a -12.2% FCF yield. The FairStock calculations show a P/E of -5.98, P/B of 3.90, ROE of -59.10%, ROCE of -28.98%, Piotroski 2/9, Altman Z-score -2.27, and FairStock Score 40/100. The only clear balance-sheet comfort is low debt, with D/E 0.01. At $3.47 on 2026-10-13, a $510.8M market cap rests on pipeline hopes, not on earnings or cash generation. Graham would ask for margin of safety; there is none in the numbers. Buffett would ask for durable competitive advantage and consistent profits; I cannot see either. This is a speculative drug-development story, not a proven compounding business. Without positive free cash flow or revenue growth, the stock is a binary clinical bet.

In plain English: Aclaris Therapeutics is a small clinical-stage drug developer working on medicines for immune and inflammatory diseases. The business looks weak today: it has lost money for years, revenue has been shrinking, and the latest quarter showed a large loss on tiny sales. At the 2026-10-13 close of $3.47, the price looks expensive relative to those numbers and depends mostly on whether its experimental drugs succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer